Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention (IRICARDIO)

424 General Military Hospital

Status: Completed

Conditions: Coronary Artery Disease; Myocardial Infarction

Treatments: Device: Stent, Medronic Resolute Integrity; Procedure: percutaneous coronary intervention; Procedure: coronary angiography

Study type: Interventional

Funder types: Other

Identifiers

NCT02498431

IRICARDIO

Details and patient eligibility

About

The investigators aim to evaluate circulating irisin levels alterations in patients with acute myocardial infraction and in patients with coronary artery disease subjected to percutaneous coronary intervention.

Full description

Irisin is a newly discovered myokine induced in exercise. There is evidence that cardiac muscle produces more irisin than skeletal muscle in response to exercise. Furthermore, irisin has been associated with isoproterenol-induced myocardial infarction (MI) in rats while it has been reported to decrease after acute myocardial infarction in humans.

The investigators aim 1) to investigate circulating irisin levels in patients at the time of acute myocardial infarction and after reprefusion [primary percutaneous coronary intervention (PCI)] 2) to compare irisin' s diagnostic and prognostic value and specificity value in myocardial infarction with known markers of cardiac injury such as creatine kinase-MB isoenzyme (CK-MB) and troponin 3) to evaluate irisin as an early necrosis biomarker 4) To evaluate irisin's sensitivity as a biomarker to detect minor myocardial necrosis after elective percutaneous coronary intervention

Enrollment: 116 patients

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acute myocardial infraction (MI) or with coronary artery disease without myocardial infraction who need percutaneous coronary intervention

Exclusion criteria

• age < 20 years old
• diseases or medications that could affect cardiac muscle or skeletal muscle metabolism
• musculoskeletal injury of surgery 6 months prior to recruitment
• severe liver or kidney disease (creatinine clearance < 60ml/min/1.73m2) or liver or kidney transplantation

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

116 participants in 3 patient groups

myocardial infraction

Experimental group

Description:

Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement

Treatment:

Device: Stent, Medronic Resolute Integrity

Procedure: coronary angiography

Procedure: percutaneous coronary intervention

coronary artery disease

Active Comparator group

Description:

Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement

Treatment:

Device: Stent, Medronic Resolute Integrity

Procedure: coronary angiography

Procedure: percutaneous coronary intervention

Control

Active Comparator group

Description:

Patients subjected to coronary angiography and found with no presence of coronary artery disease

Treatment:

Procedure: coronary angiography